Columbus Circle Investors’s Rocket Pharmaceuticals RCKT Stock Holding History

Columbus Circle Investors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,750	Closed	-$27K	–	255
2017 Q3	$27K	Sell	3,750 -91,179	-96%	-$417K	﹤0.01%	285
2017 Q2	$721K	Sell	94,929 -1,378	-1%	-$10.3K	0.01%	232
2017 Q1	$770K	Buy	96,307 +42,315	+78%	+$285K	0.01%	255
2016 Q4	$1.32M	Buy	53,992 +11,897	+28%	+$339K	0.02%	229
2016 Q3	$1.6M	Sell	42,095 -2,034	-5%	-$64K	0.02%	238
2016 Q2	$1.31M	Sell	44,129 -1,689	-4%	-$59.4K	0.01%	223
2016 Q1	$1.36M	Buy	45,818 +15,601	+52%	+$468K	0.01%	233
2015 Q4	$1.37M	Sell	30,217 -18,322	-38%	-$798K	0.01%	249
2015 Q3	$1.82M	Buy	+48,539	New	+$2.23M	0.01%	233

Other funds holding RCKT

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Columbus Circle Investors's RCKT Position: Q4 2017 in Review

Columbus Circle Investors sold out of Rocket Pharmaceuticals (RCKT) in Q4 2017, closing a stake of 3,750 shares — an estimated $27K sold.

Columbus Circle Investors first reported a position in RCKT in Q3 2015 and held it in 9 quarters. The position peaked at $1.82M in Q3 2015. 34 funds tracked by Wall St. Rank hold RCKT as of Q4 2017.

Columbus Circle Investors reported no remaining Rocket Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Columbus Circle Investors sold 3,750 Rocket Pharmaceuticals shares in Q4 2017, an estimated $27K.
Columbus Circle Investors first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 9 quarters.
Columbus Circle Investors's Rocket Pharmaceuticals position peaked at $1.82M in Q3 2015.
34 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.